Santiago T, Tarek N, Boulos F, et al. - Given that MYCN gene amplification represents the most important adverse risk factor for neuroblastoma (NB), researchers determined whether immunohistochemistry (IHC) use is feasible to identify MYCN protein expression instead of fluorescent in situ hybridization (FISH), a strategy potentially useful in regions with limited resources because FISH needs a laboratory that can perform highly complex testing, specialized personnel, and expensive reagents. They used a pilot cohort including patients with NB (n = 78). Using IHC, they assessed MYCN protein in 34 participants of Middle Eastern descent with a higher prevalence of MYCN gene amplification (44.11%) and 44 of North American descent with nine (20.45%) having MYCN amplification. They focused on the correlations of FISH outcomes and protein expression. Findings confirmed an excellent overall correlation between MYCN gene status by FISH and MYCN protein expression by IHC. In a limited-resource setting, the potential utility of MYCN IHC in NB with reflexing to FISH in equivocal cases was shown.